Revenue
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Resmed Inc (RMD)
Price$227.26Cached quote
Net income
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Free cash flow
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Financial statements
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.65B | $5.15B | $4.69B | $4.22B | $3.58B | $3.20B | $2.96B | $2.61B | $2.34B | $2.07B | $1.84B | $1.68B | $1.55B | $1.51B | $1.37B | $1.24B | $1.09B | $920.7M |
| Gross profit | $3.45B | $3.05B | $2.66B | $2.36B | $2.02B | $1.84B | $1.72B | $1.49B | $1.33B | $1.20B | $1.07B | $1.01B | $989.8M | $940.7M | $820.7M | $741.3M | $655.5M | $553.8M |
| Gross margin | 61.06% | 59.36% | 56.67% | 55.78% | 56.57% | 57.53% | 58.09% | 57.32% | 57.04% | 58.15% | 58.00% | 60.24% | 63.65% | 62.11% | 59.97% | 59.63% | 60.01% | 60.15% |
| Research & development | $378.3M | $331.3M | $307.5M | $287.6M | $253.6M | $225.3M | $201.9M | $180.7M | $155.1M | $144.5M | $118.7M | $114.9M | $118.2M | $120.1M | $109.7M | $92.0M | $75.2M | $63.1M |
| Operating expenses | $1.57B | $1.37B | $1.34B | $1.22B | $1.02B | $935.4M | $908.1M | $914.8M | $793.1M | $775.9M | $637.5M | $602.2M | $584.7M | $585.8M | $526.3M | $474.4M | $415.1M | $363.5M |
| Operating income | $1.89B | $1.69B | $1.32B | $1.13B | $1.00B | $903.7M | $809.7M | $579.3M | $541.8M | $425.8M | $429.0M | $409.2M | $405.1M | $354.8M | $294.4M | $266.9M | $240.4M | $190.3M |
| Operating margin | 33.37% | 32.75% | 28.17% | 26.80% | 27.96% | 28.27% | 27.38% | 22.22% | 23.15% | 20.60% | 23.33% | 24.38% | 26.05% | 23.43% | 21.51% | 21.47% | 22.01% | 20.67% |
| EBITDA | $2.09B | $1.88B | $1.50B | $1.30B | $1.16B | $1.06B | $964.5M | $730.1M | $661.8M | $538.0M | $515.8M | $482.3M | $478.5M | $433.1M | $380.3M | $337.5M | $301.9M | $244.3M |
| EBITDA margin | 36.93% | 36.61% | 31.95% | 30.71% | 32.42% | 33.17% | 32.62% | 28.01% | 28.28% | 26.03% | 28.05% | 28.73% | 30.77% | 28.60% | 27.79% | 27.15% | 27.64% | 26.53% |
| Net income | $1.52B | $1.40B | $1.02B | $897.6M | $779.4M | $474.5M | $621.7M | $404.6M | $315.6M | $342.3M | $352.4M | $352.9M | $345.3M | $307.1M | $254.8M | $227.0M | $190.1M | $146.4M |
| Net profit margin | 26.94% | 27.22% | 21.79% | 21.25% | 21.78% | 14.84% | 21.02% | 15.52% | 13.49% | 16.56% | 19.17% | 21.02% | 22.20% | 20.28% | 18.62% | 18.26% | 17.40% | 15.91% |
| Basic EPSper basic share | $10.47 | $9.55 | $6.94 | $6.12 | $5.34 | $3.27 | $4.31 | $2.83 | $2.21 | $2.42 | $2.51 | $2.51 | $2.44 | $2.15 | $1.75 | $1.49 | $1.26 | $0.97 |
| Diluted EPSper diluted share | $10.43 | $9.51 | $6.92 | $6.09 | $5.30 | $3.24 | $4.27 | $2.80 | $2.19 | $2.40 | $2.49 | $2.47 | $2.39 | $2.10 | $1.71 | $1.44 | $1.23 | $0.95 |
Owners
Reported shareholders
8.54%of listed shares
BlackRock, Inc.12.32M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 8.54%12.32M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 6.57%9.47M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 5.49%7.91M shares |
STATE STREET CORP | 4.63%6.68M shares |
GEODE CAPITAL MANAGEMENT, LLC | 3.02%4.35M shares |
Bank of New York Mellon Corp | 2.91%4.2M shares |
FIRST TRUST ADVISORS LP | 1.58%2.28M shares |
Invesco Ltd. | 1.43%2.06M shares |
MORGAN STANLEY | 1.34%1.93M shares |
NORTHERN TRUST CORP | 1.18%1.7M shares |
NORDEA INVESTMENT MANAGEMENT AB | 0.96%1.39M shares |
DEUTSCHE BANK AG\ | 0.92%1.32M shares |
UBS Group AG | 0.89%1.29M shares |
Swedbank AB | 0.88%1.27M shares |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.85%1.22M shares |
GOLDMAN SACHS GROUP INC | 0.80%1.16M shares |
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 0.78%1.13M shares |
DIMENSIONAL FUND ADVISORS LP | 0.78%1.12M shares |
Legal & General Group Plc | 0.65%942.61K shares |
AQR CAPITAL MANAGEMENT LLC | 0.63%910.62K shares |
Percentages use 144.24M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 8, 2026Form 4 · 10b5-1 | Farrell Michael J.Chairman and CEO | SellResMed Common Stock | 5.0K | $193.96 | $968.1K | 466.3K |
| May 7, 2026Form 4 · 10b5-1 | Farrell Michael J.Chairman and CEO | SellResMed Common Stock | 5.0K | $207.82 | $1.04M | 466.2K |
| Apr 7, 2026Form 4 · 10b5-1 | Farrell Michael J.Chairman and CEO | SellResMed Common Stock | 5.0K | $225.50 | $1.13M | 466.2K |
| Apr 1, 2026Form 4 · 10b5-1 | Sandercock BrettChief Financial Officer | SellResMed Common Stock | 1.0K | $224.31 | $224.3K | 83.5K |
| Apr 1, 2026Form 4 · 10b5-1 | FARRELL PETER CDirector | SellResMed Common Stock | 2.0K | $225.00 | $450.0K | 60.8K |